Apixaban 5 mg tablets ,Eliquis 5 mg tablets
Sponsors
Bio-innova Co., Ltd.
Conditions
Healthy subjects
Bioequivalence Apixaban 5 mg tabletsHealthy subjects
Bioequivalence Apixaban 5 mg
Phase 1
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Apixaban 5 mg tablets manufactured by T. MAN PHARMA COMPANY LIMITED, relative to Eliquis 5 mg tablets, in healthy Thai volunteers under fasting condition
TCTR20230208003
Start: 2023-07-20Target: 26Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Apixaban 5 mg tablets manufactured by T. MAN PHARMA COMPANY LIMITED, relative to Eliquis 5 mg tablets, in healthy Thai volunteers under fasting condition
TCTR20230321002
Start: 2023-07-25Target: 26Updated: 2026-08-03